What Is Semax?
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences by researchers led by Nikolai Myasoedov. The peptide is structurally derived from the 4-7 fragment of adrenocorticotropic hormone (ACTH), specifically the sequence His-Phe-Arg-Trp, which is the melanocyte-stimulating region of ACTH. Semax substitutes and extends this core sequence to create a metabolically stable compound with enhanced pharmacological activity.
In Russia, Semax has been registered as a pharmaceutical drug indicated for the treatment of stroke, transient ischemic attacks, cognitive impairment, and optic nerve diseases. It is typically administered as a nasal spray, enabling rapid central nervous system access through the olfactory epithelium and trigeminal nerve pathways, bypassing the blood-brain barrier challenge that limits many neuropeptide therapeutics.
Molecular Structure and ACTH Relationship
The relationship between Semax and ACTH is pharmacologically important. ACTH itself acts on the adrenal cortex to stimulate cortisol production, but fragments of ACTH — particularly the 4-10 sequence — have long been known to possess distinct behavioral and cognitive effects independent of adrenal function, including influences on attention, memory, and stress coping. Semax exploits this neurotrophic dimension of ACTH-derived sequences.
Unlike full-length ACTH, Semax does not significantly stimulate the hypothalamic-pituitary-adrenal (HPA) axis at therapeutic doses, thereby separating its neuroprotective and cognitive effects from the neuroendocrine and steroidogenic actions of the parent hormone. This pharmacological selectivity has been an important feature in its clinical development.
BDNF and NGF Upregulation
Among the most reproduced preclinical findings in Semax research is its capacity to upregulate brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the brain. These neurotrophins play essential roles in neuronal survival, synaptic plasticity, learning, and long-term potentiation — processes central to both neuroprotection and cognitive enhancement.
Studies in rodents have documented significant increases in BDNF mRNA and protein levels in the hippocampus, frontal cortex, and basal forebrain following Semax administration. The upregulation of BDNF is particularly relevant because reduced hippocampal BDNF is a consistent finding in models of depression, cognitive decline, and neurodegenerative disease. Semax-induced BDNF elevation may contribute to both its acute cognitive effects and longer-term neuroprotective properties.
Research using transcriptomic methodology has shown that Semax modulates the expression of hundreds of genes in brain tissue, with gene ontology analysis revealing enrichment in categories related to synaptic transmission, inflammatory regulation, and neuronal survival pathways — providing a molecular framework for its diverse biological effects.
Stroke Recovery Studies
Stroke recovery is the most clinically studied indication for Semax in the Russian medical literature. Studies in animal models of focal cerebral ischemia have consistently shown that Semax administration reduces infarct volume, improves neurological deficit scores, and promotes behavioral recovery. The neuroprotective effects appear to involve multiple mechanisms, including reduction of oxidative stress, inhibition of excitotoxicity, and modulation of neuroinflammatory cascades.
Clinical studies conducted in Russian neurological centers have evaluated Semax in acute and subacute stroke. A notable clinical trial published in Russian literature reported that stroke patients treated with intranasal Semax in addition to standard care showed improved neurological outcomes and accelerated functional recovery compared to placebo-treated controls. These findings, while promising, await replication in larger international randomized controlled trials.
Research has also examined Semax in optic nerve atrophy, where clinical studies report improvements in visual acuity and visual field parameters, suggesting utility beyond stroke-related neurological injury.
Cognitive Performance Research
Multiple animal studies have examined Semax’s effects on normal cognitive performance in the absence of neurological injury. Research in rodents using spatial learning tasks, novel object recognition, and passive avoidance paradigms has demonstrated Semax-associated improvements in acquisition speed, memory retention, and retrieval. These effects have been observed in both young and aged animals, with particularly pronounced benefits in models of age-related cognitive decline.
Electroencephalographic (EEG) research in humans has been used to study the neurophysiological correlates of Semax administration. Studies have described changes in EEG power spectra consistent with increased attentional engagement and altered information processing states, providing objective neurophysiological correlates of the reported cognitive effects.
ADHD-Related Research
Semax has attracted research interest in attention-deficit states given its proposed mechanism of enhancing dopaminergic and serotonergic transmission. Preliminary studies in children and adolescents with ADHD symptoms, conducted within the Russian clinical framework, have reported improvements in attention, behavioral regulation, and academic performance following Semax treatment. These findings are preliminary and methodological limitations preclude strong conclusions.
The dopaminergic dimension of Semax’s action — including evidence of increased dopamine turnover in prefrontal brain regions — provides a plausible mechanistic basis for ADHD-related research, though direct comparisons with established ADHD pharmacotherapies such as methylphenidate have not been rigorously conducted.
Current Status and Research Gaps
Semax represents a compound with a reasonably developed Russian clinical evidence base and a mechanistically coherent neuroprotective and nootropic profile. However, international adoption and recognition remain limited due to the absence of large-scale randomized controlled trials conducted under Western regulatory frameworks. Replication of key findings by independent research groups outside Russia is an essential next step in establishing the broader scientific validity of reported effects.
References
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. “Semax, an analogue of ACTH(4-7) with a prolonged action, attenuates anxiety and depression-like behavior in rats neonatally deprived of serotonin.” Brain Research. 2006;1116(1):126–135.
- Gusev EI, Skvortsova VI, Miasoedov NF, et al. “Neuroprotective effects of semax in acute period of hemispheric ischemic stroke.” Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 1997;97(6):26–34.
- Eremin KO, Kudrin VS, Saransaari P, et al. “Semax, an ACTH(4-7) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochemical Research. 2005;30(12):1493–1500.
- Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. “A new generation of drugs: synthetic peptides based on natural regulatory peptides.” Neuroscience and Medicine. 2013;4:223–252.
- Agapova TY, Agniullin YV, Shram SI, et al. “Effects of Semax on the expression of genes related to the serotonergic and dopaminergic systems in the mouse midbrain.” Bulletin of Experimental Biology and Medicine. 2007;144(5):640–643.